Murat A. Umetov
Murat A. Umetov has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Inara Aslanovna Khakuasheva
Berbekov Kabardino-Balkarian State University
3 shared publications - Larisa Aleksandrovna Balykova
N.P. Ogarev Mordovia State University
3 shared publications - Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
3 shared publications - Vladimir Aleksandrovich Kutsenko
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per. 10, Bld. 3, 101000 Moscow, Russia
3 shared publications - A. V. Kontsevaya
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
2 shared publications - Alena Dmitrievna Khudiakova
The Institute of Internal and Preventive Medicine — branch of the federal research center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences
2 shared publications
Latest Publications
- 23 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 35,p. 39-43
Optimization of treatment of endothelial dysfunction and arterial stiffness in patients with arterial hypertension and ischemic heart disease
The relevance of complex correction of endothelial dysfunction and arterial stiffness in patients with arterial hypertension and coronary heart disease is associated with their leading role in the development of cardiovascular diseases. Endothelial dysfunction, characterized by a deficiency of vasodilators, such as nitric oxide, and an increase in vasoconstrictor mediators, contributes to atherogenesis and thrombosis. At the same time, an increase in arterial stiffness leads to an increase in systolic pressure and impaired diastolic filling of the myocardium, which aggravates myocardial ischemia and contributes to the progression of heart failure. The introduction of an integrative approach to optimizing endothelial function and reducing arterial stiffness into clinical practice can significantly improve the prognosis and quality of life of patients, reducing the risk of serious cardiovascular events, including myocardial infarction and stroke. Results from randomized clinical trials support the efficacy of such a strategy, demonstrating that normalization of endothelial function and reduction in arterial stiffness are achievable with modern antihypertensive and lipidlowering drugs, including polypills. These drugs improve treatment adherence through simplified dosing regimens and provide effective management of multifactorial risks in patients. In addition, ongoing research and development of new therapeutics and treatments continue to highlight the need for early detection and targeted therapy in this patient population. Such strategies not only address the underlying pathophysiological changes but also aim to prevent long-term complications associated with these cardiovascular risk factors. By focusing on an individualized treatment protocol that includes both pharmacologic interventions and lifestyle changes, healthcare providers can offer a more dynamic and effective treatment plan that meets each patient’s individual needs, thereby optimizing therapeutic outcomes and improving patient compliance.Background. Cardiovascular diseases are the leading cause of death in Russia, with hypertension, coronary heart disease, and cerebrovascular disease predominating. The prevalence of hypertension is 53.9 %, but disease control remains poor, with less than 30 % of patients achieving target blood pressure levels. Therapy often includes combinations of medications, such as ACE inhibitors and angiotensin receptor blockers, which demonstrate advantages over monotherapy. Approximately 70.7 % of patients require combination therapy to effectively manage their condition.Objective. Comparison of the effects of fixed combinations of amlodipine, atorvastatin and perindopril (Lipertance® 10/20/10 mg) with a combination of amlodipine, lisinopril and rosuvastatin (Equamer® 5/10/20 mg) on the clinical progression of grade 2 and 3 arterial hypertension and functional class II and III coronary heart disease. Also study the effect on arterial stiffness, endothelial function, ankle-brachial index, vascular age.Materials and methods. The study included 65 patients with uncontrolled hypertension with systolic blood pressure (BP) ≥160 mmHg and/or diastolic BP ≥90 mmHg in combination with stable angina, taking two antihypertensive drugs at the beginning of the study. Depending on the therapy, the participants were divided into II groups: I – 30 people receiving a fixed combination of Lipertance; II group – 35 people taking a fixed combination of Equamer. All patients also received bisoprolol at a dosage of 5–10 mg and an antiplatelet agent at a dosage of 75–100 mg.Conclusions. Fixed combinations of Lipertance® and Equamer® drugs were highly effective in controlling blood pressure in patients with hypertension and coronary heart disease, achieving target systolic and diastolic levels in more than 85 % of patients. Both groups showed significant improvements in arterial stiffness and endothelial function, demonstrating their potential to reduce cardiovascular complications. Thus, these combinations can be recommended for routine use in clinical practice to improve prognosis and quality of life in patients.
- 23 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 35,p. 39-43
Optimization of treatment of endothelial dysfunction and arterial stiffness in patients with arterial hypertension and ischemic heart disease
The relevance of complex correction of endothelial dysfunction and arterial stiffness in patients with arterial hypertension and coronary heart disease is associated with their leading role in the development of cardiovascular diseases. Endothelial dysfunction, characterized by a deficiency of vasodilators, such as nitric oxide, and an increase in vasoconstrictor mediators, contributes to atherogenesis and thrombosis. At the same time, an increase in arterial stiffness leads to an increase in systolic pressure and impaired diastolic filling of the myocardium, which aggravates myocardial ischemia and contributes to the progression of heart failure. The introduction of an integrative approach to optimizing endothelial function and reducing arterial stiffness into clinical practice can significantly improve the prognosis and quality of life of patients, reducing the risk of serious cardiovascular events, including myocardial infarction and stroke. Results from randomized clinical trials support the efficacy of such a strategy, demonstrating that normalization of endothelial function and reduction in arterial stiffness are achievable with modern antihypertensive and lipidlowering drugs, including polypills. These drugs improve treatment adherence through simplified dosing regimens and provide effective management of multifactorial risks in patients. In addition, ongoing research and development of new therapeutics and treatments continue to highlight the need for early detection and targeted therapy in this patient population. Such strategies not only address the underlying pathophysiological changes but also aim to prevent long-term complications associated with these cardiovascular risk factors. By focusing on an individualized treatment protocol that includes both pharmacologic interventions and lifestyle changes, healthcare providers can offer a more dynamic and effective treatment plan that meets each patient’s individual needs, thereby optimizing therapeutic outcomes and improving patient compliance.Background. Cardiovascular diseases are the leading cause of death in Russia, with hypertension, coronary heart disease, and cerebrovascular disease predominating. The prevalence of hypertension is 53.9 %, but disease control remains poor, with less than 30 % of patients achieving target blood pressure levels. Therapy often includes combinations of medications, such as ACE inhibitors and angiotensin receptor blockers, which demonstrate advantages over monotherapy. Approximately 70.7 % of patients require combination therapy to effectively manage their condition.Objective. Comparison of the effects of fixed combinations of amlodipine, atorvastatin and perindopril (Lipertance® 10/20/10 mg) with a combination of amlodipine, lisinopril and rosuvastatin (Equamer® 5/10/20 mg) on the clinical progression of grade 2 and 3 arterial hypertension and functional class II and III coronary heart disease. Also study the effect on arterial stiffness, endothelial function, ankle-brachial index, vascular age.Materials and methods. The study included 65 patients with uncontrolled hypertension with systolic blood pressure (BP) ≥160 mmHg and/or diastolic BP ≥90 mmHg in combination with stable angina, taking two antihypertensive drugs at the beginning of the study. Depending on the therapy, the participants were divided into II groups: I – 30 people receiving a fixed combination of Lipertance; II group – 35 people taking a fixed combination of Equamer. All patients also received bisoprolol at a dosage of 5–10 mg and an antiplatelet agent at a dosage of 75–100 mg.Conclusions. Fixed combinations of Lipertance® and Equamer® drugs were highly effective in controlling blood pressure in patients with hypertension and coronary heart disease, achieving target systolic and diastolic levels in more than 85 % of patients. Both groups showed significant improvements in arterial stiffness and endothelial function, demonstrating their potential to reduce cardiovascular complications. Thus, these combinations can be recommended for routine use in clinical practice to improve prognosis and quality of life in patients.
- Open Access
- 15 January 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (1) , 47-54
Comparative assessment of arterial stiffness and endothelial dysfunction during treatment with fixed combinations of antihypertensive drugs in patients with arterial hypertension and coronary artery disease
Aim. To evaluate and compare the efficacy and safety of two triple fixed combinations (FC) of antihypertensive drugs, amlodipine/indapamide/perindopril and amlodipine/valsartan/hydrochlorothiazide (HCTZ), in managing the clinical course in patients with grade 2-3 hypertension and functional class II and III coronary artery disease. Materials and methods. The study included 52 patients with uncontrolled hypertension with systolic blood pressure (SBP)≥160 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg combined with stable effort angina who were taking two antihypertensive drugs at the beginning of the study. Depending on the treatment, the participants were divided into two groups: Group 1 included 27 subjects who received FC of amlodipine/indapamide/perindopril, and Group 2 included 25 subjects who received FC of amlodipine/valsartan/HCTZ. All patients also received β-blocker bisoprolol 5-10 mg and antiplatelet agent 75-100 mg. Results. After 12 weeks of follow-up compared to baseline, there was a significant decrease in office BP in Groups 1 and 2: SBP by 34.50 and 32.03 mmHg (p0.001 for both groups), with significant differences between the groups (p=0.045), DBP by 13.28 and 13.79 mmHg, respectively (p0.001 for both groups), without significant differences between the groups (p=0.052). The heart rate decreased in both groups to 69.00 bpm, with no intergroup differences (p=0.061). In Groups 1 and 2, after 12 weeks of follow-up, arterial stiffness significantly improved compared to baseline: SBP in the aorta decreased by 23.50 and 27.00 mmHg (p0.001 for both groups), DBP in the aorta decreased by 17.50 and 20.00 mmHg (p0.001 for both groups), pulse pressure in the aorta decreased by 4.50 and 8.00 mmHg (p0.001), augmentation index decreased by 9.00% and 10.00% (p0.001 for both groups), pulse wave velocity decreased by 2.51 and 1.97 m/s (p0.001 for both groups), with significant differences between groups (p=0.032), the ankle-brachial index decreased by 0.01 and 0.02 (p0.001 for both groups), vascular age decreased by 5.00 years (p=0.001) and 3.00 years (p=0.025) [p=0.025 for comparison between groups], endothelial function improved by 24.5% (p=0.015) and 18.0% (p0.001) [p=0.015 for comparison between groups]. The number of ischemia episodes significantly decreased in both groups: in Group 1 from 2.8±0.3 to 1.2±0.2 per week (p=0.021), in Group 2 from 2.5±0.6 to 1.5±0.3 (p=0.018), with no significant differences between the groups. Conclusion. Both triple FCs – amlodipine/indapamide/perindopril and amlodipine/valsartan/HCTZ – effectively reduced office BP and improved vascular stiffness and endothelial function in patients with hypertension and coronary artery disease. FC of amlodipine/indapamide/perindopril provided a more pronounced reduction in office SBP, pulse wave velocity, and vascular age, as well as endothelial function improvement. Both regimens reduced the incidence of ischemic episodes, with no significant differences between the groups.
- 15 January 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (1) , 47-54
Open AccessComparative assessment of arterial stiffness and endothelial dysfunction during treatment with fixed combinations of antihypertensive drugs in patients with arterial hypertension and coronary artery disease
Aim. To evaluate and compare the efficacy and safety of two triple fixed combinations (FC) of antihypertensive drugs, amlodipine/indapamide/perindopril and amlodipine/valsartan/hydrochlorothiazide (HCTZ), in managing the clinical course in patients with grade 2-3 hypertension and functional class II and III coronary artery disease. Materials and methods. The study included 52 patients with uncontrolled hypertension with systolic blood pressure (SBP)≥160 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg combined with stable effort angina who were taking two antihypertensive drugs at the beginning of the study. Depending on the treatment, the participants were divided into two groups: Group 1 included 27 subjects who received FC of amlodipine/indapamide/perindopril, and Group 2 included 25 subjects who received FC of amlodipine/valsartan/HCTZ. All patients also received β-blocker bisoprolol 5-10 mg and antiplatelet agent 75-100 mg. Results. After 12 weeks of follow-up compared to baseline, there was a significant decrease in office BP in Groups 1 and 2: SBP by 34.50 and 32.03 mmHg (p0.001 for both groups), with significant differences between the groups (p=0.045), DBP by 13.28 and 13.79 mmHg, respectively (p0.001 for both groups), without significant differences between the groups (p=0.052). The heart rate decreased in both groups to 69.00 bpm, with no intergroup differences (p=0.061). In Groups 1 and 2, after 12 weeks of follow-up, arterial stiffness significantly improved compared to baseline: SBP in the aorta decreased by 23.50 and 27.00 mmHg (p0.001 for both groups), DBP in the aorta decreased by 17.50 and 20.00 mmHg (p0.001 for both groups), pulse pressure in the aorta decreased by 4.50 and 8.00 mmHg (p0.001), augmentation index decreased by 9.00% and 10.00% (p0.001 for both groups), pulse wave velocity decreased by 2.51 and 1.97 m/s (p0.001 for both groups), with significant differences between groups (p=0.032), the ankle-brachial index decreased by 0.01 and 0.02 (p0.001 for both groups), vascular age decreased by 5.00 years (p=0.001) and 3.00 years (p=0.025) [p=0.025 for comparison between groups], endothelial function improved by 24.5% (p=0.015) and 18.0% (p0.001) [p=0.015 for comparison between groups]. The number of ischemia episodes significantly decreased in both groups: in Group 1 from 2.8±0.3 to 1.2±0.2 per week (p=0.021), in Group 2 from 2.5±0.6 to 1.5±0.3 (p=0.018), with no significant differences between the groups. Conclusion. Both triple FCs – amlodipine/indapamide/perindopril and amlodipine/valsartan/HCTZ – effectively reduced office BP and improved vascular stiffness and endothelial function in patients with hypertension and coronary artery disease. FC of amlodipine/indapamide/perindopril provided a more pronounced reduction in office SBP, pulse wave velocity, and vascular age, as well as endothelial function improvement. Both regimens reduced the incidence of ischemic episodes, with no significant differences between the groups.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (11)
Possibilities and limitations of secondary prevention of chronic non-communicable diseases in primary care of Russia and CIS countries
Objective. To analyze the possibilities and limitations of implementation of secondary prevention of chronic non-communicable diseases (CNCDs) in primary care in cities in the Russian Federation and 4 CIS countries based on a survey of doctors. Material and methods. The study involved doctors of outpatient-polyclinic facilities from 16 cities in the Russian Federation and 6 major cities in 4 CIS countries (Kyrgyz Republic, Republic of Belarus, Republic of Kazakhstan, Republic of Azerbaijan). The survey was organized on a questionnaire prepared by «National Medical Research Center for Therapy and Preventive Medicine», which included 11 blocks of questions. Multiple choice for each question is provided. Results. Men aged 50—59 years prevailed among patients, who were observed in outpatient clinics of five countries. Men aged over 65 years made up 30 and 40% respectively in the samples from the Russian Federation and the Republic of Azerbaijan, and only one fifth — in the samples from the other three countries. Men aged 40—50 years were ranked second for frequency of uptake in the samples from Republic of Kazakhstan and Republic of Belarus. The frequency of uptake among women was comparable in the age ranges of 50—59 years, as well as 60—65 years and older in samples from the Russian Federation, Republic of Belarus and Republic of Azerbaijan. Chronic forms of ischemic heart disease ranked first among CNCDs in terms of uptake (56% on average), the second place is occupied by the type 2 diabetes mellitus (27% on average). At least partial coverage by preferential drugs was provided according to the doctors in most of the considered samples from CIS countries; 100% coverage supplied the needs up to 40% in three CIS countries, this indicator was 2 times less in other countries. In the Kyrgyz Republic and Republic of Azerbaijan, 50% of the target level was reached. The situation was slightly better in the other three countries, with doctors reporting 75% of the target level reaching for the main risk factors. In all countries, about 30% of the cases were without problems with hospitalization, partial difficulties prevailed in the rest of the cases. An incomplete coverage by doctors in the staffing list in the analyzed countries has been noted, and there has been a significant shortage of doctors in the Russian Federation and Republic of Kazakhstan. The similar picture has been observed regarding the nursing staff. Conclusion. Systematic screening and regular medical check-up of adults are necessary, especially in the age group of 40—49 years for men and 50—59 years for women with regard to the significant role of chronic non-communicable diseases in the development of complications and mortality in CIS countries. Measures to increase adherence to the treatment, that affects the achievement of target levels of major risk factors, should be taken. The increase of preferential provision of pharmaceutical products and the organization of health-promoting schools for patients with chronic non-communicable diseases are important measures. In most CIS countries, the increase of the staffing list coverage by doctors and nursing staff can improve the implementation of secondary prevention of chronic non-communicable diseases.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (11)
Possibilities and limitations of secondary prevention of chronic non-communicable diseases in primary care of Russia and CIS countries
Objective. To analyze the possibilities and limitations of implementation of secondary prevention of chronic non-communicable diseases (CNCDs) in primary care in cities in the Russian Federation and 4 CIS countries based on a survey of doctors. Material and methods. The study involved doctors of outpatient-polyclinic facilities from 16 cities in the Russian Federation and 6 major cities in 4 CIS countries (Kyrgyz Republic, Republic of Belarus, Republic of Kazakhstan, Republic of Azerbaijan). The survey was organized on a questionnaire prepared by «National Medical Research Center for Therapy and Preventive Medicine», which included 11 blocks of questions. Multiple choice for each question is provided. Results. Men aged 50—59 years prevailed among patients, who were observed in outpatient clinics of five countries. Men aged over 65 years made up 30 and 40% respectively in the samples from the Russian Federation and the Republic of Azerbaijan, and only one fifth — in the samples from the other three countries. Men aged 40—50 years were ranked second for frequency of uptake in the samples from Republic of Kazakhstan and Republic of Belarus. The frequency of uptake among women was comparable in the age ranges of 50—59 years, as well as 60—65 years and older in samples from the Russian Federation, Republic of Belarus and Republic of Azerbaijan. Chronic forms of ischemic heart disease ranked first among CNCDs in terms of uptake (56% on average), the second place is occupied by the type 2 diabetes mellitus (27% on average). At least partial coverage by preferential drugs was provided according to the doctors in most of the considered samples from CIS countries; 100% coverage supplied the needs up to 40% in three CIS countries, this indicator was 2 times less in other countries. In the Kyrgyz Republic and Republic of Azerbaijan, 50% of the target level was reached. The situation was slightly better in the other three countries, with doctors reporting 75% of the target level reaching for the main risk factors. In all countries, about 30% of the cases were without problems with hospitalization, partial difficulties prevailed in the rest of the cases. An incomplete coverage by doctors in the staffing list in the analyzed countries has been noted, and there has been a significant shortage of doctors in the Russian Federation and Republic of Kazakhstan. The similar picture has been observed regarding the nursing staff. Conclusion. Systematic screening and regular medical check-up of adults are necessary, especially in the age group of 40—49 years for men and 50—59 years for women with regard to the significant role of chronic non-communicable diseases in the development of complications and mortality in CIS countries. Measures to increase adherence to the treatment, that affects the achievement of target levels of major risk factors, should be taken. The increase of preferential provision of pharmaceutical products and the organization of health-promoting schools for patients with chronic non-communicable diseases are important measures. In most CIS countries, the increase of the staffing list coverage by doctors and nursing staff can improve the implementation of secondary prevention of chronic non-communicable diseases.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (10)
Behavioral risk factors in the Russian population: focus on tobacco consumption. The ESSE-RF3 study results
Objective. To study the smoking status, type of consumed tobacco products and smoking intensity in the Russian population of men and women aged 35—74 years. Material and methods. Representative samples (n=27 804, men and women 35—74 years old) from 15 regions of the Russian Federation were surveyed in 2020—2022, and the response was more than 70%. Smoking was assessed using the STEPwise approach to surveillance (STEPS) questionnaire, adapted by the specialists of National Medical Research Center for Therapy and Preventive Medicine. The analysis included the following sections: status of tobacco consumption (never smoked; smoked but gave up a year ago or more; smokes now), type of consumed tobacco, including electronic nicotine delivery systems (ENDS), age at first smoking, smoking cessation, information about attempts to stop smoking, smoking index (SI). The statistical analysis was carried out in the R 4.1 open source software environment. Continuous variables were described using mean and standard deviation (M±SD) or median and quartiles (Med [Q1; Q3]). Qualitative variables were described by relative frequency (%). The comparison of discrete variables between groups was done using the Fisher’s exact test. Prevalence test for trend was performed using linear or logistic regression. Significance level was taken equal to 0.05. Results. The proportion of men equal 45.4% and women equal 83.9% has never smoked, 26.7 and 8.4%, respectively, has stopped smoking. Industrial cigarettes were consumed by 90.2% of smokers (men — 90.4%, women — 89.3%), ENDS — 4.9% (3.8% and 8.5%). More than 20 cigarettes a day were smoked by 43.2% of men and 16.8% of women. SI>10 pack/year has been determined in 81.1% of men and 55.3% of women, SI>25 pack/year — in 41.5 and 14.1%, respectively. The proportion of subjects equal 31.5% tries to stop smoking, and 41.5% got tips to refuse smoking. Conclusion. Among smokers in Russia, 9 out of 10 consume cigarettes, and an increase of consuming electronic nicotine delivery systems up to 4.9% has been found. Extension of prevention influence is necessary to achieve smoking cessation in those who receive preventive consultation.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (10)
Behavioral risk factors in the Russian population: focus on tobacco consumption. The ESSE-RF3 study results
Objective. To study the smoking status, type of consumed tobacco products and smoking intensity in the Russian population of men and women aged 35—74 years. Material and methods. Representative samples (n=27 804, men and women 35—74 years old) from 15 regions of the Russian Federation were surveyed in 2020—2022, and the response was more than 70%. Smoking was assessed using the STEPwise approach to surveillance (STEPS) questionnaire, adapted by the specialists of National Medical Research Center for Therapy and Preventive Medicine. The analysis included the following sections: status of tobacco consumption (never smoked; smoked but gave up a year ago or more; smokes now), type of consumed tobacco, including electronic nicotine delivery systems (ENDS), age at first smoking, smoking cessation, information about attempts to stop smoking, smoking index (SI). The statistical analysis was carried out in the R 4.1 open source software environment. Continuous variables were described using mean and standard deviation (M±SD) or median and quartiles (Med [Q1; Q3]). Qualitative variables were described by relative frequency (%). The comparison of discrete variables between groups was done using the Fisher’s exact test. Prevalence test for trend was performed using linear or logistic regression. Significance level was taken equal to 0.05. Results. The proportion of men equal 45.4% and women equal 83.9% has never smoked, 26.7 and 8.4%, respectively, has stopped smoking. Industrial cigarettes were consumed by 90.2% of smokers (men — 90.4%, women — 89.3%), ENDS — 4.9% (3.8% and 8.5%). More than 20 cigarettes a day were smoked by 43.2% of men and 16.8% of women. SI>10 pack/year has been determined in 81.1% of men and 55.3% of women, SI>25 pack/year — in 41.5 and 14.1%, respectively. The proportion of subjects equal 31.5% tries to stop smoking, and 41.5% got tips to refuse smoking. Conclusion. Among smokers in Russia, 9 out of 10 consume cigarettes, and an increase of consuming electronic nicotine delivery systems up to 4.9% has been found. Extension of prevention influence is necessary to achieve smoking cessation in those who receive preventive consultation.
- 20 March 2024
- Published by PANORAMA Publishing House in Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
- No. 3,p. 25-34
Cardiovascular risk in the contexst of one case
The article presents a clinical case of a patient with excess body weight, who, along with conventional examination methods, underwent bioimpedance measurements, which made it possible to more accurately stratify cardiovascular risk.
- 20 March 2024
- Published by PANORAMA Publishing House in Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
- No. 3,p. 25-34
Cardiovascular risk in the contexst of one case
The article presents a clinical case of a patient with excess body weight, who, along with conventional examination methods, underwent bioimpedance measurements, which made it possible to more accurately stratify cardiovascular risk.
- Open Access
- 22 February 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (1) , 4-12
Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study
Aim. To evaluate the usage of antihypertensive drugs (AHDs) and their combinations in participants aged 35 to74 years with arterial hypertension (AH) in the population-based study ESSE-RF3.Material and methods. Representative samples of the population aged 35 to 74 years from 15 regions of Russia (n=28731) with a response rate over 70% were examined in the ESSE-RF3 study. Therapy received by 9944 participants with AH (with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or when the subject was taking AHDs) was analyzed. Information about AHDs intake (brand name of the drug) was recorded by questionnaire and coded according to International Nonproprietary Names by classes. Statistical analysis was performed using the open-source R 4.1 environment. Comparison of discrete indicators between groups was performed using Fisher’s exact test. The significance level for all tested hypotheses was taken as.05. The study was approved by the Ethics Committee of FGBI “NMRC TPM” of the Ministry of Health of the Russian Federation, each participant signed an informed consent.Results. Among the patients receiving therapy for AH, angiotensin-converting enzyme inhibitors (ACEIs) were used by 38.8% of participants, angiotensin receptor blockers (ARBs) — 31.6%, betablockers (BBs) — 29.0%, сalcium channel blockers (CCBs) — 21.5%, diuretics — 18.6%, 1.1% — outdated AHDs; 8.6% — other groups of drugs. Monotherapy was used by 53.1% of patients, 33.1% of participants received two, and 13.9% received three AHDs. Among participants taking two or more AHDs (including single-pill combinations (SPC)), males most often received the combination of BB+ ACEI and females — BB+ARBs. SPC AHDs were used by 10.3% of those receiving therapy (males: 9.8%, females: 10.6%). Among SPCs, the top three combinations were CCBs + ACEIs (28%), diuretics + ACEIs (27.5%), and diuretics + ARBs (24.4%).Conclusion. The population study ESSE-RF3, based on the survey of a representative sample of the Russian population aged 35-74 years, showed that more than a half of participants with AH receiving therapy were used the monotherapy, only every tenth of those treated received SPC. The problem of insufficient patients’ literacy was indicated — about 1% of patients received outdated AGPs. In addition, 8.6% of patients used non-AHDs for the treatment of AH. For improving the control of AH treatment, it is necessary to increase the adherence of patients to the prescribed therapy and more strict adherence of doctors to the published guidelines for AH treatment.
- 22 February 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (1) , 4-12
Open AccessFeatures of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study
Aim. To evaluate the usage of antihypertensive drugs (AHDs) and their combinations in participants aged 35 to74 years with arterial hypertension (AH) in the population-based study ESSE-RF3.Material and methods. Representative samples of the population aged 35 to 74 years from 15 regions of Russia (n=28731) with a response rate over 70% were examined in the ESSE-RF3 study. Therapy received by 9944 participants with AH (with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or when the subject was taking AHDs) was analyzed. Information about AHDs intake (brand name of the drug) was recorded by questionnaire and coded according to International Nonproprietary Names by classes. Statistical analysis was performed using the open-source R 4.1 environment. Comparison of discrete indicators between groups was performed using Fisher’s exact test. The significance level for all tested hypotheses was taken as.05. The study was approved by the Ethics Committee of FGBI “NMRC TPM” of the Ministry of Health of the Russian Federation, each participant signed an informed consent.Results. Among the patients receiving therapy for AH, angiotensin-converting enzyme inhibitors (ACEIs) were used by 38.8% of participants, angiotensin receptor blockers (ARBs) — 31.6%, betablockers (BBs) — 29.0%, сalcium channel blockers (CCBs) — 21.5%, diuretics — 18.6%, 1.1% — outdated AHDs; 8.6% — other groups of drugs. Monotherapy was used by 53.1% of patients, 33.1% of participants received two, and 13.9% received three AHDs. Among participants taking two or more AHDs (including single-pill combinations (SPC)), males most often received the combination of BB+ ACEI and females — BB+ARBs. SPC AHDs were used by 10.3% of those receiving therapy (males: 9.8%, females: 10.6%). Among SPCs, the top three combinations were CCBs + ACEIs (28%), diuretics + ACEIs (27.5%), and diuretics + ARBs (24.4%).Conclusion. The population study ESSE-RF3, based on the survey of a representative sample of the Russian population aged 35-74 years, showed that more than a half of participants with AH receiving therapy were used the monotherapy, only every tenth of those treated received SPC. The problem of insufficient patients’ literacy was indicated — about 1% of patients received outdated AGPs. In addition, 8.6% of patients used non-AHDs for the treatment of AH. For improving the control of AH treatment, it is necessary to increase the adherence of patients to the prescribed therapy and more strict adherence of doctors to the published guidelines for AH treatment.